247573-13-3

Usage

Uses

Used in Pharmaceutical Industry:
5-chloro-6,7-diMethoxyquinazolin-4(3H)-one is used as a potential drug candidate for its antifungal and antibacterial properties, offering a new avenue for the development of antimicrobial agents to combat resistant strains.
Used in Medicinal Chemistry:
5-chloro-6,7-diMethoxyquinazolin-4(3H)-one is utilized as a precursor or intermediate in the synthesis of other biologically active compounds, contributing to the discovery of novel therapeutic agents with diverse applications in medicine.
Used in Drug Development:
As a quinazolinone derivative with demonstrated antifungal and antibacterial activities, 5-chloro-6,7-diMethoxyquinazolin-4(3H)-one is employed in drug development to explore its potential as a lead compound for the creation of new pharmaceuticals targeting various infectious diseases.

Upstream product

• 637347-71-8 2-chloro-3,4-dimethoxy-6-nitrobenzoic acid 
• 82330-54-9 2-chloro-3,4-dimethoxy-6-nitrobenzaldehyde 
• 5417-17-4 2-chloro-3,4-dimethoxybenzaldehyde 
• 149-73-5 trimethyl orthoformate 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 205194-08-7 6,7-dimethoxy-5-nitro-3,4-dihydroquinazolin-4-one 
• 247573-12-2 5-amino-6,7-dimethoxy-4(3H)-quinazolinone 

Relevant academic research and scientific papers

2 - Substituted cephem compound-containing pharmaceutical composition

PROBLEM TO BE SOLVED: To provide a cephem compound which has a strong antimicrobial activity, in particular effective against various β-lactamase producing Gram negative bacteria, and a composition comprising the compound.SOLUTION: The present invention provides a pharmaceutical composition comprising a compound represented by formula (I), an ester at a carboxyl group, an amino-protected compound when the amino is present on a ring in the 7-side chain, or a pharmaceutically acceptable salt thereof.

Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α

A series of isoquinolin-1-ones and quinazolin-4-ones and related derivatives were prepared and evaluated for their ability to inhibit tumor necrosis factor α (TNFα) production in human peripheral blood monocytes stimulated with bacterial lipopolysaccharide (LPS). In an effort to optimize the TNFα inhibitory activity, a homologous series of N-alkanoic acid esters was prepared. Several electrophilic and nucleophilic substitutions were also carried out. Alkanoic acid esters of four carbons were found to be optimum for activity in both the isoquinoline and quinazoline series. Ring substituents such as fluoro, bromo, nitro, acetyl, and aminomethyl on the isoquinoline ring resulted in a significant loss of activity. Likewise, similar groups on the quinazoline ring also reduced inhibitory activity. However, the 6- and 7-aminoquinazoline derivatives, 75 and 76, were potent inhibitors, with IC50 values in the TNFα in vitro assay of approximately 5 μM for each. An in vivo mouse model of pulmonary inflammation was then used to evaluate promising candidate compounds identified in the primary in vitro assay. Compound 75 was selected for further study in this inhalation model, and was found to reduce the level of TNFα in brochoalveolar lavage fluid of LPS-treated mice by about 50% that of control mice. Thus, compounds such as 75, which can effectively inhibit proinflammatory cytokines such as TNFα in clinically relevant animal models of inflammation and fibrosis, may have potential as new antiinflammatory agents. Finally, a quinazoline derivative suitable to serve as a photoaffinity radiolabeled compound was prepared to help identify the putative cellular target(s) for these TNFα inhibitors.